|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00570193 |
|
Date of registration:
|
06/12/2007 |
|
Primary sponsor: |
|
|
Public title:
|
Photodynamic and Pharmacologic Treatment of CNV
PBS |
|
Scientific title:
|
Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study) |
|
Date of first enrolment:
|
December 2006 |
|
Target sample size:
|
41 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00570193 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
|
|
|
Contacts
|
|
Name:
|
Nabil M Jabbour, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Mid-Atlantic Retina Consultations |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- All previously untreated CNV secondary to MD
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Choroidal Neovascularization
|
|
Macular Degeneration
|
|
Intervention(s)
|
|
Drug: ranibizumab (Lucentis)
|
|
Drug: verteporfin (Visudyne)
|
|
Primary Outcome(s)
|
|
Visual change
[Time Frame: 18 months]
|
|
Secondary Outcome(s)
|
|
Frequency of treatment
[Time Frame: 18 months]
|
|
Secondary ID(s)
|
|
PBS-100-388
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|